Objectives: Because several studies for autoimmune pancreatitis (AIP) have revealed pancreatic calcification resembling that in chronic pancreatitis (CP), we sought to clarify whether AIP could transform into chronic features similar to advanced CP with severe pancreatic dysfunction. 
Introduction
Pancreatitis presumably caused by autoimmune mechanism had been originally reported in Europe. 1 The disease concept of autoimmune pancreatitis (AIP) was proposed in AIP 9 , and all patients showed no image finding resembling those in chronic pancreatitis at diagnosis. All patients were diagnosed as having type 1 AIP. Two control groups were enrolled in this study: 47 patients with definite CP diagnosed based on the revised Japanese clinical diagnostic criteria for CP 12 (44 men and 3 women; median age: 66 years, range: 39-81 years; 42 with alcoholism 5 without) and 30 apparently healthy subjects without any pancreatic and other diseases, such as diabetes mellitus (DM) (23 men and 7 women; median age: 53 years, range: 31-91 years).
Evaluation of pancreatic imaging
The presence of pancreatic calcification in AIP and CP patients was evaluated using the most recent abdominal computerized tomography (CT) images obtained for each patient.
Clinical features and laboratory tests
We analyzed the factors of DM and insulin use, use and duration of corticosteroid treatment, relapse, alcohol intake, smoking and serum blood chemistry markers of pancreatic function and AIP activity. Alcohol intake was defined as over 25g daily ethanol consumption and smoking was defined as more than 20 cigarettes smoked per day. Exocrine function was assessed using fecal elastase-1 concentration (FEC) 17 (Pancreatic elastase ELISA kit, BIOSERV Diagnostics GmbH, Germany) and the N-benzoyl-L-tyrosyl-p-aminobenzoic acid (BT-PABA) test. Endocrine function was evaluated using serum values of HbA1c, fasting immunoreactive insulin (IRI) for patients treated without insulin, and fasting C-peptide reactivity (CPR). We calculated homeostatic model assessment (HOMA)-R and HOMA-to evaluate insulin resistance and insulin secretory function, respectively. Pancreatic function and AIP activity markers were determined at the time of the most recent hospital visit for each patient.
As controls, we evaluated similar parameters among definite CP patients and examined FEC levels in healthy subjects. All laboratory tests were performed using commercially available kits and performed according to the manufacturer's instructions.
Statistical analysis
Pearson's chi-square test was adopted to test for differences between patient subgroups.
The Mann-Whitney U and Kruskal-Wallis tests were employed to compare continuous data. All tests were performed using Statflex ver. 6 software (Artech Co., Ltd., Osaka, Japan). P values of less than 0.05 were considered to be statistically significant.
Ethics
This study was approved by the ethics committee of Shinshu University (approval number: 1973).
Results

Patient characteristics
Among the 92 recruited AIP patients, 17 displayed imaging findings that fulfilled the revised Japanese clinical diagnostic criteria for CP showing characteristic image findings of pancreatic stone and were classified into the AIP with severe calcification (SC) group (14 men and 3 women; median age: 74 years, range: 60-88 years). Nine of these patients had obvious stones in the pancreatic duct (Fig. 1a) and 16 exhibited diffuse calcification in the parenchyma (Fig. 1b) . The remaining 75 patients were defined as the AIP without SC group. In comparisons of clinical parameters among the AIP with SC, AIP without SC, and CP groups, the observation period was found to be significantly longer for the AIP with SC group than for the AIP without SC group (p < 0.05). Both AIP groups were significantly older than the CP group (p < 0.05), while the male-to-female ratio of the CP group was significantly higher than those of the AIP subgroups. AIP with SC patients received prednisolone for a significantly longer period than AIP without SC patients (p < 0.05). The CP group included significantly more alcoholics (p < 0.0005 vs. both AIP subgroups, respectively). We found a tendency for several disease activity markers, including IgG, IgG4, soluble interleukin-2 receptor (sIL2-R), and circulating immune complex (CIC), to be lower at final visit in AIP with SC than in AIP without SC (Table 1) .
Evaluation of exocrine function
FEC values were significantly lower in the AIP and CP groups than in healthy controls.
FEC in the CP group was significantly lower, and FEC in the AIP with SC group tended to be lower, than that in the AIP without SC group (Table 2 , Fig. 2 ). The incidence of patients with exocrine insufficiency defined as FEC <200 g/g was 56% (5/9) in AIP with SC and 39% (13/33) in AIP without SC. This difference was not significant. The CP group showed the highest exocrine insufficiency incidence of 74% (20/27), which was significantly greater than that in AIP without SC and indicated that exocrine dysfunction in AIP with SC was intermediary between the other groups ( BT-PABA test values for the AIP with SC and CP groups were lower than that for AIP without SC, albeit non-significantly (Table 2 ). There were no remarkable differences in the prevalence of exocrine insufficiency defined as BT-PABA <70% among the groups.
Interestingly, all AIP with SC patients showed impaired exocrine sufficiency.
Evaluation of endocrine function
The prevalence of complicating DM and insulin use among all AIP patients were 47%
(43/92) and 22% (20/92), respectively. These values tended to be higher in the AIP with SC group (Table 3) . Fasting IRI in the CP group was significantly lower than values in both AIP subgroups, which were comparable (Table 3 , Fig. 3a) . The incidence of patients with endocrine insufficiency as defined by fasting IRI <5.0 U/mL was 59%
(20/34) in the CP group. This was significantly higher than the 26% (16/62) for AIP patients without SC. At a frequency of 31% (4/13), endocrine dysfunction AIP with SC appeared to be intermediary between AIP without SC and CP. AIP on the whole exhibited endocrine insufficiency in 27% (20/75) of cases (Table 3) .
Evaluation of fasting CPR showed results similar to those of IRI (Table 3 , Fig. 3b ). The prevalence of patients with endocrine insufficiency according to fasting CPR <1.5 U/mL was 68% (25/37) in the CP group, which was significantly higher than the 30% (21/70) for AIP without SC and comparably higher than the intermediary value of 41%
(7/17) for AIP with SC. Endocrine insufficiency was 32% (28/87) among all AIP cases (Table 3) .
HOMA-R values in the AIP subgroups were both significantly higher than that in CP (Table 3 , Fig. 4a ). The prevalence of insulin resistance defined as HOMA-R 2.5
was also significantly higher in the individual and overall AIP groups than in CP. The results of HOMA-testing supported those for fasting IRI and CPR: HOMA-in CP was significantly lower than that in AIP without SC and tended to be lower than that in AIP with SC (Table 3 , Fig. 4b ). The prevalence of patients with decreased insulin secretion according to HOMA-<40% was less for all AIP groups versus CP, albeit not significantly (Table 3 ). g/g in 10 of 28 AIP patients (36%) after a more comparable long-term follow-up period (median: 41 months, range: 5-130 months), 18 which was similar to our result of 43%. In addition, the higher ratio of FEC <200 g/g in the AIP with SC group (56% vs.
39% in the AIP without SC group) suggested that the occurrence of pancreatic calcification had deteriorated exocrine function.
There were no significant differences in BT-PABA results among present study groups.
The BT-PABA test has been reported to have several problems that hamper accurate measurement and result in low sensitivity and specificity. 19 However, Uchida et al.
observed an amelioration of BT-PABA in 10 of 21 AIP patients (48%) 6 months after corticosteroid treatment, but then witnessed exocrine insufficiency in 6 of the patients afterwards and further deterioration in 4 of the 6 patients over 3 years of follow-up.
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Accordingly, a proportion of AIP cases appears to progress to exocrine insufficiency, which may be exacerbated by the onset of calcification.
Evaluation of pancreatic endocrine function in long-term follow-up AIP patients
The complications of DM and insulin treatment were seen in 47% and 22% of AIP patients, respectively, which were not remarkably different from those values in CP.
Although the AIP group exhibited significantly higher fasting IRI and CPR levels than did CP, impaired secretion was found in only 27% and 32% of cases, respectively. Thus, while endocrine dysfunction can occur in AIP during long-term follow-up, it appears to progress more slowly than in CP. Since endocrine function in AIP with SC was more severely impaired than that in AIP without SC, insufficiency may progress quickly after severe pancreatic calcification to a frequency approaching that in CP. Meanwhile, HOMA-levels were generally better maintained in the AIP groups than in CP and supported the results of fasting IRI and CPR. We observed significantly higher HOMA-R levels in the AIP groups, which may have been related to increased insulin resistance due to corticosteroid treatment for AIP. In conclusion, AIP may progress to a state of pancreatic insufficiency after the appearance of calcification that is less severe than in ordinary CP. homeostasis model assessment-beta cells; NS: not significant
